trending Market Intelligence /marketintelligence/en/news-insights/trending/yxzicibuhy5rvmhh6oc8ma2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Exelixis plans US drug application on positive cancer treatment results

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency

Groups Urge Business Roundtable CEOs To Act On New Corporate Purpose Declaration

State of South Korean OTT Video: Subscription

Global Streaming Media Device Sales Forecast To Flatten In 5 Year Outlook


Exelixis plans US drug application on positive cancer treatment results

Exelixis Inc. said Oct. 10 its cabozantinib drug performed better against sunitinib in treating advanced kidney cancer, prompting the company to plan an application for the treatment in the U.S.

Results from randomized phase two trial with patients suffering from previously untreated advanced renal cell carcinoma showed cabozantinib decreasing rate of disease progression or death by 31% when compared to sunitinib, which is marketed by Pfizer Inc

Exelixis and partner Ipsen will jointly host a live webcast at 1 p.m. ET on Oct. 10 to discuss the study and its data.